Jingwei Guo; Jun Liang; Yunhong Tan; Zuhui Xu; Baozhen Peng; Xichao Ou; Peilei Hu; Zhenhua Chen; Hua Bai; Binbin Liu; Wenjie Zhao; Liqin Liu; Yanhong Li; Xiaojie Wan; Jue Wang; Jie Duan; Yi Liu; Dehua Gong; Jingwei Guo; Jun Liang; Yunhong Tan; Zuhui Xu; Baozhen Peng; Xichao Ou; Peilei Hu; Zhenhua Chen; Hua Bai; Binbin Liu; Wenjie Zhao; Liqin Liu; Yanhong Li; Xiaojie Wan; Jue Wang; Jie Duan; Yi Liu; Dehua Gong

doi:10.46234/ccdcw2026.062

[1]

World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization; 2025. https://www.who.int/publications/i/item/9789240116924.

[2]

Barteka G, Bwayo D, Matovu JKB, Wanume B, Alunyo JP, Sseguya R, et al. Treatment outcomes and predictors of success for multidrug resistant tuberculosis MDR TB in Ugandan regional referral hospitals. Sci Rep 2025;15(1):14144. https://doi.org/10.1038/s41598-025-97027-x.

[3]

Yang CG, Luo T, Shen X, Wu J, Gan MY, Xu P, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis 2017;17(3):275 − 84. https://doi.org/10.1016/S1473-3099(16)30418-2.

[4]

Gao WF, Wang WN, Li J, Gao Y, Zhang S, Lei H, et al. Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant Mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China. Antimicrob Resist Infect Control 2024;13(1):125. https://doi.org/10.1186/s13756-024-01482-6.

[5]

He WC, Tan YH, Liu CF, Wang YT, He P, Song ZX, et al. Drug-resistant characteristics, genetic diversity, and transmission dynamics of rifampicin-resistant mycobacterium tuberculosis in Hunan, China, revealed by whole-genome sequencing. Microbiol Spectr 2022;10(1):e0154321. https://doi.org/10.1128/spectrum.01543-21.

[6]

Marco MH, Ahmedov S, Castro KG. The global impact of COVID-19 on tuberculosis: a thematic scoping review, 2020-2023. PLoS Glob Public Health 2024;4(7):e0003043. https://doi.org/10.1371/journal.pgph.0003043.

[7]

Alene KA, Xu ZH, Bai LQ, Yi HZ, Tan YH, Gray D, et al. Spatial clustering of drug-resistant tuberculosis in Hunan province, China: an ecological study. BMJ Open 2021;11(4):e043685. https://doi.org/10.1136/bmjopen-2020-043685.

[8]

Xi Y, Zhang W, Qiao RJ, Tang J. Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis. PLoS One 2022;17(6):e0270003. https://doi.org/10.1371/journal.pone.0270003.

[9]

Akalu TY, Clements ACA, Xu ZH, Bai LQ, Alene KA. Predictors of poor treatment outcomes among drug-resistant tuberculosis patients in Hunan province, China. Heliyon 2024;10(23):e40391. https://doi.org/10.1016/j.heliyon.2024.e40391.

[10]

Cui KP, Zhao XX, Liu W, Bai L. Global, regional, and national burden and trends of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in adolescents and adults aged 15-49 years from 2010 to 2021: insights from the global burden of disease study 2021. BMC Med 2025;23(1):445. https://doi.org/10.1186/s12916-025-04269-7.